Gmax Biopharm LLC

Zhejiang University

Hangzhou Ags Medtech Co., Ltd.

Gmaz Biopharm LLC

China University of Geosciences

Alipay Information Technology Co., Ltd.

Zhang, Cheng

Cheng Zhang

Min Wang

Jianwei Yin

Shikun Tian

Hua Zhang

Shuqian Jing

Xiaofeng Wang

Chenjiang Yao

Yan Jiang

Xinxin Shi

Hao Pan

Shuiguang Deng

Baiming Shi

Xuepeng Guo

Feng Yao

Lei Sun

Rongzhu Wang

Chao Yan

Liangliang Bi

Yong Guo

Kesuo Fan

Bo Li

Huiming Tang

Yongquan Zhang

Dwayne Tannant

Yongtao Li

Liangqing Wang

Guagchang Zhang

Ding Xia

Chengren Xiong

Sha Lu

The present disclosure provides a clip device. The clip device may include a clip and a storage tube. The clip may include clip arms including a first clip arm and a second clip arm; the storage tube including a channel, a proximal end of the first clip arm, and a proximal end of the second clip arm being stowable within the channel; the clip being capable of being switched from a locked state to an unlocked state; wherein in the locked state, the distal end of the first clip arm and the distal end of the second clip arm are closed and the storage tube restricts a movement of the clip relative to the storage tube toward the distal end of the first clip arm and the distal end of the second clip arm; in the unlocked state, a movement restriction of the clip by the storage tube is released and the distal end of the first clip arm and the distal end of the second clip arm are able to be reopened.

Clip devices, clip apparatuses, and methods for unlocking of clip devices

Provided herein are an apelin receptor (APJ) antibody and its fusion protein with Elabela. Also provided herein is a pharmaceutical composition of a fusion protein with APJ antibody and Elabela, and use thereof in treating, preventing, or alleviating one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension or one or more symptoms of heart failure.

APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01

The present invention discloses a fair task offloading and migration method for edge service networks, taking the Pareto optimality of the utility function of all user tasks executed by the edge system as the optimization objective, this approach not only takes into account the constraints of edge network resources, but also ensures the maximization of the utility function of all user tasks in the system, it proposes a new quantitative measurement index for improving the task utility quality under multi-user competition. In addition, the present invention uses the graph neural network and reinforcement learning algorithm to solve the final optimization goal, this algorithm has high execution efficiency and returns accurate approximate results, which is particularly suitable for the scene of edge network system under multi-user complex tasks, so that when multi-user tasks compete for network resources, the edge computing network system can efficiently obtain the Pareto optimal result of multi-user utility function, greatly improving the service quality and user experience of edge network environments.

Fair task offloading and migration method for edge service networks

Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.

GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof

The present invention discloses a network burst load evacuation method for edge servers, which takes a time and average penalty function of all tasks performed by the edge system as a minimum optimization goal. This method not only takes into account the fairness of all users in the system, but also ensures that the unloading tasks of all users in the system can be completed in a relatively shortest time, and a new quantitative measure is proposed for improving user QoS response. In the implementation process of the algorithm in the present invention, a particle swarm algorithm is used to solve an optimal target of the system, This algorithm has a fast execution speed and high efficiency, and is especially suitable for a scene of an edge computing network system, so that when a sudden load occurs, an edge computing network system can respond in a very short time and complete the evacuation of the load, which greatly improves the fault tolerance and stability of the edge network environment.

Network burst load evacuation method for edge servers

The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.

Human endothelin receptor antibody and use thereof

Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.

GCGR antibody and GLP-1 fusion protein thereof, pharmaceutical composition thereof and application thereof

Disclosed is a stable pharmaceutical solution formulation of a GLP-1R antibody fusion protein, comprising a therapeutically effective amount of the GLP-1R antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mM, the final concentration of the surfactant is 0.01%-0.5%, and the pH value of the stable solution formulation is from 5.0 to 8.0. The stable solution formulation of the present invention can be used in the treatment of diabetes, obesity and conditions associated therewith.

Stable pharmaceutical solution formulation of GLP-1R antibody fusion protein

Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.

Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1

Antibody specifically binding to GLP-1 R and fusion protein thereof with GLP-1

Growing community of inventors

Hangzhou, China

Cheng Zhang